GLP-1 and PCOS

Polycystic ovary syndrome is not simply a reproductive condition — it is a complex metabolic disorder in which elevated insulin levels drive the ovaries to over-produce androgens (male hormones like testosterone). This hormonal imbalance disrupts ovulation, causing irregular or absent periods, acne, excess hair growth, and difficulty conceiving.

Approximately 70% of women with PCOS have some degree of insulin resistance, regardless of body weight. However, obesity significantly amplifies insulin resistance and worsens PCOS symptoms. This is why weight loss — even modest amounts of 5–10% of body weight — can dramatically improve hormonal profiles and restore menstrual regularity.

GLP-1 receptor agonists work in multiple synergistic ways: they reduce appetite and caloric intake, slow gastric emptying, enhance insulin secretion in a glucose-dependent manner, and directly improve insulin sensitivity in peripheral tissues. This makes them uniquely well-suited to address the root metabolic dysfunction of PCOS.

Careful tracking is essential when using GLP-1 medications for PCOS. Because PCOS is a multisystem disorder, effective monitoring covers hormonal, metabolic, and reproductive markers simultaneously. Shotlee's free injection tracker makes it easy to log your weekly or monthly doses and correlate them with health data over time.

GLP-1s are not currently FDA-approved specifically for PCOS; their use in this context is off-label, though widely practiced. Most prescriptions are written under obesity or pre-diabetes indications. Insurance coverage therefore varies significantly and may require prior authorization based on BMI and metabolic comorbidities.

A critical safety note: because GLP-1 therapy can restore ovulation in women who were previously anovulatory, unintended pregnancy becomes a real possibility. If you are not trying to conceive, effective contraception is essential — and bear in mind that GLP-1s may reduce the effectiveness of oral contraceptive pills by altering gastric emptying, which could reduce pill absorption. Non-oral contraception (IUD, patch, ring, implant, injection) is generally recommended.

Women with PCOS typically have higher baseline fasting insulin levels than the general population. This can mean a more pronounced initial response to GLP-1 therapy in terms of hypoglycemic risk — especially when combined with metformin or other insulin sensitizers. Blood glucose monitoring during the initial titration period is advisable.